€2.15
Your prediction
Vivoryon Therapeutics N.V. Stock
Pros and Cons of Vivoryon Therapeutics N.V. in the next few years
Pros
Cons
Performance of Vivoryon Therapeutics N.V. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Vivoryon Therapeutics N.V. | -0.920% | 0.000% | -3.348% | -81.807% | -73.072% | -88.605% | -65.249% |
| Nanorepro AG | 1.370% | 3.693% | -9.653% | -34.821% | -11.408% | -80.460% | 187.402% |
| Heidelberg Pharma AG | 1.280% | -4.490% | -3.306% | -31.778% | -36.413% | -64.759% | -2.905% |
| Vaxart Inc. | -0.980% | -1.038% | -3.915% | 21.004% | 57.099% | -88.681% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Analyzing the financials of Vivoryon Therapeutics (US Symbol: VIV) reveals a company navigating through significant challenges in the Biotechnology & Medical Research sector. While the company presents an intriguing profile in terms of its potential, a closer examination of the financial ratios, balance sheets, and cash flow statements paints a picture that is both nuanced and cautionary.
The financial landscape of Vivoryon Therapeutics reflects a company that is still in its developmental phase, struggling to achieve profitability while engaging in promising research and potential product development. Key metrics show that while there are positive aspects to consider, such as gross profits, the overall performance indicators raise concerns about the sustainability of its business model and its ability to attract future investment.
Gross Profit: One of the brighter spots in the financial statements is the gross profit of about $9.2 million. This indicates that when the company generates revenue, it retains a significant portion as gross profit, displaying the potential for operational effectiveness once revenue generation increases.